Dietary administration of the licorice flavonoid isoliquiritigenin deters the growth of MCF-7 cells overexpressing aromatase

International Journal of Cancer

Volumn 124, Issue 5, 2009, Pages 1028-1036

  Lan, Ye ^a   Wai, M Gho ^a   Franky, L Chan ^a   Shiuan, Chen ^b   Lai, K Leung ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

Aromatase; Breast cancer cells; Isoliquiritigenin

Indexed keywords

AROMATASE; AROMATASE INHIBITOR; DNA FRAGMENT; FLAVONOID; ISOLIQUIRITIGENIN; MESSENGER RNA; CCAAT ENHANCER BINDING PROTEIN; CHALCONE DERIVATIVE; TESTOSTERONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DIETARY INTAKE; ENZYME ACTIVITY; ENZYME INHIBITION; GLYCYRRHIZA; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; ANIMAL; BREAST TUMOR; CHEMISTRY; DRUG EFFECT; ENZYMOLOGY; FEMALE; GENETICS; METABOLISM; NUDE MOUSE; OVARIECTOMY; PROMOTER REGION; TUMOR CELL LINE;

ANIMALS; AROMATASE; AROMATASE INHIBITORS; BREAST NEOPLASMS; CCAAT-ENHANCER-BINDING PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; CHALCONES; FEMALE; GLYCYRRHIZA; HUMANS; MAP KINASE SIGNALING SYSTEM; MICE; MICE, NUDE; OVARIECTOMY; PROMOTER REGIONS, GENETIC; RNA, MESSENGER; TESTOSTERONE;

EID: 58749093583     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24046     Document Type: Article

References (42)

1. Colditz GA. Hormones and breast cancer: evidence and implications for consideration of risks and benefits of hormone replacement therapy. J Women Health 1999;8:347-57.
2. The Endogenous Hormones and Breast Cancer Collaborative Group. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 2002;94:606-16.
3. Yoshidome K, Shibata MA, Couldrey C, Korach KS, Green JE. Oestrogen promotes mammary tumor development in C3( 1 )/SV40 large T-antigen transgenic mice: paradoxical loss of oestrogen receptor alpha expression during tumor progression. Cancer Res 2000;60:6901- 10.
4. Liehr JG, Ulubelen AA, Strobel HW. Cytochrome P-450-mediated redox cycling of oestrogens. J Biol Chem 1986;261:16865-70.
5. Li JJ, Li SA. Oestrogen carcinogenesis in Syrian hamster tissues: role of metabolism. Fed Proc 1987;46:1858-63.
6. Zhu BT, Conney AH. Functional role of oestrogen metabolism in target cells: review and perspectives. Carcinogenesis 1998; 19: 1-27.
7. Leung UK, Wang TT. Paradoxical regulation of Bcl-2 family proteins bv 17b-oestradiol in human breast cancer cells MCF-7. Br J Cancer 1999;81:387-92.
8. Kudachadkar R, O'Regan RM. Aromatase inhibitors as adjuvant therapy for postmenopausal patients with early stage breast cancer. CA Cancer J Clin 2005,55:145-63 (review).
9. Miller WR, Dixon JM. Local endocrine effects of aromatase inhibitors within the breast. J Steroid Biochem Mol Biol 2001;79:93-102.
10. Santner SJ, Chen S, Zhou D, Korsunsky Z, Martel J, Santen RJ. Effect of androstenedione on growth of untransfected and aromatase-trans- fected MCF-7 cells in culture. J Steroid Biochem Mol Biol 1993; 44:611-16.
11. Yue W, Santner SJ, Masamura S, Wang JP, Demers LM, Hamilton C, Santen RJ. Determinants of tissue estradiol levels and biologic responsiveness in breast tumors. Breast Cancer Res Treat 1998;49 (Suppl 1 :S 1 -7 (review); discussion S33-7.
12. Lee KM, Abel J, Ko Y, Harth V, Park WY, Seo JS, Yoo KY, Choi JY, Shin A, Aim SH, Noh DY, Hirvonen A, et al. Genetic polymorphisms of cytochrome P450 19 and 1B1, alcohol use, and breast cancer risk in Korean women. Br J Cancer 2003;88:675-8.
13. Hirose K, Matsuo K, Toyama T, Iwata H, Hamajima N, Tajima K. The CYP19 gene eodon 39 Trp/Arg polymorphism increases breast cancer risk in subsets of premenopausal Japanese. Cancer Epidemiol Biomarkers Prev 2004;13:1407-11.
14. Chen S, Zhou D, Okubo T, Kao Y.-C, Yang C. Breast tumor aromatase: functional role and transcriptional regulation. Endocr Relat Cancer 1999;6:149-56.
15. Simpson ER, Zhao Y, Agarwal VR, Michael MD, Bulun SE, Hinshel-wood MM, Graham-Lorence S, Sun T, Fisher CR, Qin K, Mendelson CR. Aromatase expression in health and disease. Recent Prog Horm Res 1997;52:185-213; discussion 213-14.
16. Diaz-Cruz ES, Shapiro CL, Brueggerneier RW. Cyclooxygenase inhibitors suppress aromatase expression and activitv in breast cancer cells. J Clin Endocrinol Metab 2005;90:2563-70.
17. Yu SM, Kuo SC. Vasorelaxant effect of isoliquiritigenin, a novel soluble guanylate cyclase activator, in rat aorta. Br J Pharmacol 1995;114:1587-94.
18. Tawata M, Aida K, Noguchi T, Ozaki Y, Kume S, Sasaki H, Chin M, Onaya T. Anti-platelet action of isoliquiritigenin, an aldose reductase inhibitor in licorice. Eur J Pharmacol 1992;212:87-92.
19. Takahashi T, Takasuka N, ligo M, Baba M, Nishino H, Tsuda H, Okuyama T. Isoliquiritigenin, a flavonoid from licorice, reduces prostaglandin E2 and nitric oxide, causes apoptosis, and suppresses aberrant crypt foci development. Cancer Sci 2004;95:448-53.
20. Yamamoto S, Aizu E, Jiang H, Nakadate T, Kyoto I, Wang JC, Kato R. The potent anti-tumor-promoting agent isoliquiritigenin. Carcinogenesis 1991;12:317-23.
21. Baba M, Asano R, Takigami I, Takahashi T, Ohmura M, Okada Y, Sugiraoto H, Arika T, Nishino H, Okuyama T. Studies on cancer che-moprevention by traditional folk medicines XXV. Inhibitory effect of isoliquiritigenin on azoxymethane-induced murine colon aberrant crvpt focus formation and carcinogenesis. Biol Pharm Bull 2002; 25:247-50.
22. Yue W, Zhou D, Chen S, Brodie A. A new nude mouse model for postmeno-pausal breast cancer using MCF-7 cells transfected with the human aromatase gene. Cancer Res 1994;54:5092-5.
23. Zhou DJ, Pompon D, Chen SA. Stable expression of human aromatase complementary DNA in mammalian cells: a useful system for aromatase inhibitor screening. Cancer Res 1990;50:6949-54.
24. Grube BJ, Eng ET, Kao YC, Kwon A, Chen S. White button mushroom phytochemicals inhibit aromatase activity and breast cancer cell proliferation. J Nutr 2001; 131;3288-93.
25. Mosmann T. Rapid colorimetric assay for cellular growth and survival; application to proliferation and cytotoxicity assays. J Immunol Methods 1983;65:55-63.
26. Wang Y, Gho WM, Chan FL, Chen S, Leung LK. The red clover iso-flavone biochanin A inhibits aromatase activity and expression. Br J Nutr 2008;99:303-10.
27. Wang Y, Lee KW, Chan FL, Chen S, Leung LK. The red wine polyphenol resveratrol displays bi-level inhibition on aromatase in breast cancer cells. Toxicol Sci 2006;92:71-7.
28. Chen S, Zhou D, Okubo T, Kao Y-C, Yang C. Breast tumor aromatase: functional role and transcriptional regulation. Endocr Relat Cancer 1999;6:149-56.
29. Eng ET, Williams D, Mandava U, Kirma N, Tekmal RR, Chen S. Suppression of aromatase (estrogen synthetase) by red wine phytochemicals. Breast Cancer Res Treat 2001;67:133-46.
30. Eng ET, Ye J, Williams D, Phung S, Moore RE, Young MK, Grunt-manis U, Braustein G, Chen S. Suppression of estrogen biosynthesis by procyanidin dimmers in red wine and grape seeds. Cancer Res 2003;63:8516-22.
31. Le Bail JC, Pouget C, Fagnere C, Basly JP, Chulia AJ, Habrioux G. Chalcones are potent inhibitors of aromatase and 17beta-hydroxysteroid dehydrogenase activities. Life Sci 2001;68:751-61.
32. Simpson ER, Zhao Y, Agarwal VR, Michael MD, Bulun SE, Hinshel-wood MM, Graham-Lorence S, Sun T, Fisher CR, Qin K, Mendelson CR. Aromatase expression in health and disease. Recent Prog Horm Res 1997;52:185-213; discussion 213-14.
33. Diaz-Cruz ES, Shapiro CL, Brueggerneier RW. Cyclooxygenase inhibitors suppress aromatase expression and activity in breast cancer cells. J Clin Endocrinol Metab 2005;90:2563-70.
34. Grimm SL, Rosen JM. The role of C/EBPβ in mammary gland development of breast cancer. J Mammary Gland Biol Neoplasia 2003; 8:191-204.
35. Kijima I, Ye J, Glackin C, Chen S. CCAAT/Enhancer binding protein d up-regulates aromatase promoters I. 3/II in breast cancer epithelial cells. Cancer Res 2008;68:4455-64.
36. Li H, Gade P, Xiao W, Kalvakolanu DV. The interferon signaling network and transcription factor C/EBP-β. Cell Mol Immunol 2007; 4:407-18.
37. Jo EH, Hong HD, Aim NC, Jung JW, Yang SR, Park JS, Kim SH, Lee YS, Kang KS. Modulations of the Bcl-2/Bax family were involved in the chemopreventive effects of licorice root (Glycyrrhiza uraiensis Fisch) in MCF-7 human breast cancer cell, J Agric Food Chem 2004;52:1715-19.
38. Jo EH, Kim SH, Ra JC, Kim SR, Cho SD, Jung JW, Yang SR, Park JS, Hwang JW, Aruoma OI, Kim TY, Lee YS, et al. Chemopreventive properties of the ethanol extract of Chinese licorice (Glycyrrhiza uralensis) root: induction of apoptosis and G1 cell cycle arrest in MCF-7 human breast cancer cells. Cancer Lett 2005;230:239-47.
39. Takahashi T, Baba M, Nishino H, Okuyama T. Cyclooxygenase-2 plays a suppressive role for induction of apoptosis in isoliquiritige- nin-treated mouse colon cancer cells. Cancer Lett 2006;23i:319-25.
40. Jung JI, Chung E, Seon MR, Shin HK, Kim EJ, Lira SS, Chung WY, Park KK, Park JH. Isoliquiritigenin (1SL) inhibits ErbB3 signaling in prostate cancer cells. Biofactors 2006;28:159-68.
41. Ti T, Satomi Y, Katoh D, Shimada J, Baba M, Okuyama T, Nishino H, Kitamura N. Induction of cell cycle arrest and p21(CIPl/WAFl) expression in human lung cancer cells by isoliquiritigenin. Cancer Lett 2004;207:27-35.
42. Maggiolini M, Statti G, Vivacqua A, Gabriele S, Rago V, Loizzo M, Menichini F, Amdo S. Estrogenic and antiproliferative activities of isoliquiritigenin in MCF7 breast cancer cells. J Steroid Biochem Mol Biol 2002;82:315-22.